Hepatocellular Carcinoma: A Review of 140 Cases

Mughal, Tariq I.; Patel, S

doi:10.5144/0256-4947.1996.53

Cited by 3 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result is similar to the recent findings of Al Sohaibani et al in 2011 and Al Sawat et al in 2013 [9] [20]. However, this differs from previously reported HCC data in Saudi Arabia from 1990 to 2004, which showed that HBV-associated liver disease was the predominant cause of HCC in KSA [19] [21] [22]. This recent drop in CHB as a cause for HCC and liver disease is related to the implementation of the HBV vaccination neonatal program in the country approximately 25 years ago [7] [8].…”

Section: Discussionsupporting

confidence: 90%

Causes and Stages of Hepatocellular Carcinoma at Patient Presentation at a Tertiary Medical Center in Western Saudi Arabia

Alkhayyat¹,

Fallatah²,

Akbar³

et al. 2014

JCT

View full text Add to dashboard Cite

Background: With 748,300 new cases diagnosed every year, hepatocellular carcinoma (HCC) is the 5 th and the 7 th most common cancer among males and females, respectively, and causes 7% of all cancer-related deaths. HCC represents more than 90% of primary liver cancers. Objective: The aim of the present study was to recognize the stages of HCC at presentation in patients who were diagnosed at King Abdul Aziz University Hospital (KAUH) and to identify the associated laboratory features of advance HCC. Materials and Methods: A retrospective analysis of 57 HCC patients admitted to KAUH between January 2008 and December 2012 was conducted. The diagnosis was established using ultrasound (U/S), computed tomography (CT) and/or magnetic resonance imaging (MRI), with or without a liver biopsy, as well as blood testing for alpha-fetoprotein. The following data were extracted from the medical records at KAUH: patient demographics (age, sex and nationality), laboratory results (CBC, LFT, PT, INR and alpha-fetoprotein), radiological results, biopsy results for those patients who underwent biopsy, outcomes (living, deceased or lost from the follow-up), and mortality and survival rates. Results: A total of 57 HCC patients were admitted during the study period, and 3 patients were excluded from the analysis. Of the remaining 54 patients, 44 (81.5%) were males and 10 (18.5%) were females. The mean age was 64.54 years (SD, 11.2 years; range, 31-86 years). The majority of patients were Saudis (19, 35.2%), non-Saudis (35, 64.8%), Egyptians (9, 16.6%) and Yemenis (7, 13%). The remaining 19 (35.2%) patients comprised other nationalities. Chronic hepatitis C virus was the most common cause for liver cirrhosis (35 patients, 64.8%). CT was the primary diagnostic method (37 patients 68.5%), while 9 (16.7%) cases were confirmed by adnominal MRI. Six patients (11.1%) were diagnosed with abdominal ultrasound * Corresponding author. S. Alkhayyat et al. 1304 examination and elevated alpha-fetoprotein levels. In 2 (3.7%) patients, HCC was confirmed by liver biopsy. The majority of the patients (37, 68.5%) had advanced disease. Only 21 (39%) patients underwent radio frequency appellation (RFA). The mean survival time from diagnosis to death was 5.9 months (SD, 5.7 months), and the longest survival time to death was 20 months. Conclusion: The majority of our patients presented at an advanced disease stage, and CHC was the most common underlying cause for liver cirrhosis in our cohort of HCC patients. The proper implementation of HCC screening programs for cirrhotic patients is expected to help detect the treatable stages of HCC in a timely manner.

show abstract

Section: Discussionsupporting

confidence: 90%

Causes and Stages of Hepatocellular Carcinoma at Patient Presentation at a Tertiary Medical Center in Western Saudi Arabia

Alkhayyat¹,

Fallatah²,

Akbar³

et al. 2014

JCT

View full text Add to dashboard Cite

show abstract

“…HCV infection (149,150). Considerably higher alcohol use is found in other countries, especially among PWID and prisoners.…”

Section: Recommendations On Care Of People Infected With Hcvmentioning

confidence: 99%

Direct-acting antivirals and chronic hepatitis C: towards elimination

Franco¹,

Galbraith²,

Overton³

et al. 2018

View full text Add to dashboard Cite

7. RECOMMENDATIONS ON TREATMENT 59 7.1 Assessment for HCV treatment 7.2 Treatment with direct-acting antiviral agents 62 7.3 Removal of recommendation for treatment with telaprevir or boceprevir 7.4 Preferred and alternative regimens for the treatment of persons with chronic hepatitis C virus infection 7.5 Treatment with pegylated interferon and ribavirin 8. CLINICAL CONSIDERATIONS 8.1 Clinical assessment of patients prior to treatment 8.2 Monitoring for adverse events 8.3 Drug-drug interactions 8.4 Monitoring for treatment response 9. SPECIAL CONSIDERATIONS FOR SPECIFIC POPULATIONS 9.1 People who inject drugs 9.2 Persons with HIV/HCV coinfection 9.3 Children and adolescents 9.4 Persons with cirrhosis 9.5 Persons with chronic kidney disease 9.6 Persons with HBV/HCV coinfection 9.7 Persons with TB/HCV coinfection 10. OPERATIONAL AND IMPLEMENTATION ISSUES 10.1 Factors to be considered in prioritizing who receives treatment 10.2 Service planning 10.3 Service delivery 10.4 Concerns of infringement of patient rights due to implementation of anti-diversion measures 11. DISSEMINATION AND UPDATING OF THE GUIDELINES REFERENCES Web Appendices, 2016 All appendices are made available on the WHO hepatitis website.

show abstract

“…It is mostly seen in men (male/female ratio 2.4:1) and generally occurs in the elderly ages (1). But in high incidence areas, male/female ratio can increase up to 5.7:1 and the disease can affect people in their thirties (3,4). HCC still has a poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of P2/MS and AFP in Early Prediction of Hepatocellular Carcinoma Recurrence

Topal

Taşdemir

Gümüş

et al. 2020

Konuralp Tıp Dergisi

View full text Add to dashboard Cite

Objective: P2/MS is a simple, inexpensive and non-invasive test for the evaluation of hepatic fibrosis in cirrhosis. Elevated alpha-fetoprotein levels in hepatocellular carcinoma is related with recurrence. We aimed to examine the efficacy of P2/MS and alpha-fetoproteinin early prediction of hepatocellular carcinoma recurrence and to determine a cut-off value for P2/MS and alpha-fetoprotein. Methods: Sixty nine patients with hepatocellular carcinoma were retrospectively scanned for recurrence existence. The recurrence of hepatocellular carcinoma was diagnosed radiologically, via 3-phase tomography and magnetic resonance investigation. The formula of P2/MS was platelet count (10 9 /L) 2 /[monocyte count (%)x neutrophil count(%)]. Results: Forty two patients had hepatocellular carcinoma recurrence. For the recurrence prediction, the cut-off value of P2/MS was ≤59.9 with 100% specificity and 95.24% sensitivity. The cut-off value of alpha-fetoprotein was found >57.5 with 83.3% sensitivity and 92.6% specificity. Conclusions: With these findings, P2/MS and alpha-fetoprotein seems as reliable markers for the prediction of hepatocellular carcinoma recurrence. We suggest that they can be used as non-invasive tools for the early estimation of hepatocellular carcinoma recurrence.

show abstract

Hepatocellular Carcinoma: A Review of 140 Cases

Cited by 3 publications

References 12 publications

Causes and Stages of Hepatocellular Carcinoma at Patient Presentation at a Tertiary Medical Center in Western Saudi Arabia

Causes and Stages of Hepatocellular Carcinoma at Patient Presentation at a Tertiary Medical Center in Western Saudi Arabia

Direct-acting antivirals and chronic hepatitis C: towards elimination

Efficacy of P2/MS and AFP in Early Prediction of Hepatocellular Carcinoma Recurrence

Contact Info

Product

Resources

About